DNMT3A and myeloid neoplasm: In myeloid malignancies, m5C levels could provide valuable diagnostic and prognostic tools to tailor therapies and assess anti-cancer drug responses and toxicity, as DNMT3A was recently reported to be a key player in the progression of malignant glioma19.